Ivabradin Ratiopharm (Ivabradine)

Ivabradine works by selectively blocking the funny (If) current in the sinoatrial node. This current controls the pacemaker activity that sets the heart’s rhythm. Inhibition slows the spontaneous depolarisation of the node, leading to a lower heart rate while leaving contractility and blood pressure largely unchanged.

The appropriate dose of Ivabradin Ratiopharm is determined by the prescribing clinician based on the individual’s clinical condition, baseline heart rate, and response to therapy. Dosage adjustments are made according to therapeutic goals and tolerability, and patients should follow the prescriber’s instructions precisely.

Safety data for ivabradine during pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers usually advise avoiding use unless absolutely necessary and may consider alternative therapies.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Ivabradin Ratiopharm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for heart‑rate reduction is the beta‑blocker class. Unlike beta‑blockers, ivabradine lowers heart rate without affecting beta‑adrenergic receptors, so it does not influence blood pressure or cause bronchospasm. This makes it useful when beta‑blockers are contraindicated or not tolerated, though beta‑blockers also provide additional anti‑ischemic benefits.

Ivabradin Ratiopharm should be stored at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and keep them out of reach of children. No refrigeration is required.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water. Patients are advised to take the dose at the same times each day to maintain consistent blood levels.

Serious risks include symptomatic bradycardia that can lead to dizziness or fainting, atrial fibrillation, and severe hypotension or heart block. Patients should report any episodes of fainting, palpitations, or unusually slow heartbeats to their healthcare provider promptly.

Ivabradin Ratiopharm is contraindicated in patients with severe hepatic impairment, those with a resting heart rate below 50 beats per minute, and individuals with sick sinus syndrome or second‑ or third‑degree atrioventricular block unless they have a permanent pacemaker. It should also be avoided in patients taking strong CYP3A4 inhibitors without dose adjustment.